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a  b  s  t  r  a  c  t
Therapeutic  approach  for  chronic  myeloid  leukemia  (CML)  patients  has  undergone  a revolutionary  change
with the  introduction  of tyrosine  kinase  inhibitors,  which  improved  overall  survival  and  quality  of
life. Optimal  therapy  adherence  has  become  of  paramount  importance  to  maximize  the beneﬁts  in  the
long-term  outcome.  Several  evidences  have  been  reported  that  personal  factors,  such  as  social  support,
psychological  and  subjective  perceptions  about  the  drug  used  and  the  future,  could  inﬂuence  adherence.
We  here  report  the  results  of a questionnaire  speciﬁcally  designed  to evaluate  factors  inﬂuencing  adher-
ence and  perceptions  about  the future,  distributed  to patients  during  regional  Italian  meetings.  Overall,
1133  patients  compiled  the questionnaire:  median  age  was  57  years.  High  rate  of  adherence  was reported,
but 42%  of interviewed  patients  admitted  that  they  had  occasionally  postponed  a dose  and  58%  had  dis-
continued  therapy  mainly  for forgetfulness.  The  majority  of patients  discussed  with  personal  physician
about  the  importance  of  adherence  and  received  sufﬁcient  information  about  illness  and treatment,  but
would  like  to  have  discussed  more  about  discomfort,  anxiety  and  fear  of  the future.  Summarizing  per-
sonal drug  compliance  and  estimating  how  many  days  a month,  on  average,  the  patients  did  not  take
the drug,  the  majority  answered  that  it was  less  than  3 days  (55%) and  only  a minority  (4%)  admitted
that  it  was  more  than  7 days.  Interviewed  about  discontinuation,  49%  of  patients  answered  that  wouldn’t
interrupt  because  of  fear  of  losing  all  the  results  achieved  so  far. This  study  suggests  a higher  level of
satisfaction  with  more  information  received  but the  need  of  improving  communication  about  possible
future  treatment  free  remission.
©  2015  Elsevier  Ltd.  All  rights  reserved.
1. Introduction
Imatinib was the ﬁrst molecular targeted therapy (i.e., tyrosine
kinase inhibitors (TKIs) approved by the US Food and Drug admin-
istration (FDA) for chronic myeloid leukemia (CML) in early 2000.
This drug dramatically improved CML  patient outcomes by show-
ing major clinical advantages and improved quality of life (QoL)
compared to previous treatments, such as interferon (IFN) [1,2].
However, as imatinib or other TKIs are to be administered on a
daily basis, maintenance of optimal QoL over the long-term period,
has become a critical aspect of care in this cancer population. Some
studies have shown that QoL of CML  patients treated with imat-
inib is similar with that of their peers in the general population
for patients aged 60 years or older, but major limitations exist for
younger CML  patients in several aspects of daily life activities [3].
Another key challenge introduced by the introduction of TKIs
in the treatment of CML  patients is that of adherence to therapy.
Indeed, low adherence was shown to be associated to decreased
rate of cytogenetic and molecular responses and, consequently,
increased rate of progression and resistance [4,5]. Some studies
have shown that a large proportion of CML  patients do not fully
adhere with treatment [4] and that this could be explained by both
intentional and unintentional reasons [6]. However, patient adher-
ence has been collected in different ways amongst the few studies
conducted so far, thus hampering a clear understanding of factors
associated with medication-taking behavior. This is also further
complicated by the fact that, measuring adherence to therapy is
challenging and all methods have “pro” and “cons” [7–9]. Also, the
interplay between all the potential factors that can contribute to
improve adherence in CML  is poorly understood and more data are
needed on this topic.
Therefore, as in the CML  arena very few studies addressed
this issue in the real-world setting [10,11] we have performed a
large patient-based survey to investigate adherence behaviors and
potential relationships with QoL, treatment satisfaction, and social
life. Also, we focused on patient’s attitude toward the possibility of
drug discontinuation in future treatment free programs.
2. Patients and methods
In a series of meetings developed only for patients, an ad hoc
survey including 25 items was designed and proposed. Patients
were recruited from physicians from different centers on a speciﬁc
invitation and therefore, based on the fact that were not selected,
were representative of general CML  population. The survey was
designed based on real-life level of evidences and on literature
review about adherence in CML. We  included in the ﬁnal analysis
only questionnaires completely answered in each item. The items of
the survey were grouped into the following board categories: (1)
general questions about personal behavior; (2) relationship with
treating physician; (3) perceptions of quality of life and adherence
behaviors; (4) perceptions about future possible discontinuation of
drug assumption. CML  patients in treatment with any kind of TKI
stemming from 30 Italian hematology centers: as some questions
differed across centers, only the questions that were used in the
majority of centers were analyzed. Overall, the analyzed questions
from 28 centers were reported in this study: 13 centers from north-
ern Italy, 7 from central Italy, 8 from southern Italy. Items included
in the Survey are summarized in Appendix A.
In the ﬁnal analysis were also considered the following features
requested at the time of survey completion: gender, age, level of
education and disease’s duration. Descriptive statistics were pro-
vided for questions considering all the questions reported in at
least 6 centers. Categorical variables (gender, education and all the
questionnaire questions) were summarized by using frequency dis-
tributions (i.e. the number of patients in each level of the categorical
variable) and percentages. Quantitative variables (age and disease
duration) were summarized by using n, arithmetic mean, standard
deviation, median, range, minimum and maximum.
3. Results
3.1. Population characteristics
Overall, 1133 patients completed the questionnaire, of them
658 males (58.1%) and 475 females (41.9%). Fifty-three percent
of patients had a high level of education (high school-university),
whereas 21% had only primary/elementary level and 25.7% a middle
school level. Median age of patients was 57 years (range 17–90) and
according to cumulative frequencies the most represented age cate-
gory was  that from 65 to 75 years (22.89%) followed by 55–65 years
(21.72%) and 45–55 (19.75%). The majority of patients (79.55%) had
a median duration of disease of less than 10 years.
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Fig. 1. Most relevant questions about adherence.
3.2. General questions about personal behavior
At ﬁrst question (“Have you forgotten to take your drug?”),
60% of patients answer “no, never”, whereas 25.6% admitted that
rarely forgot to take prescribed therapy. Ninety-one percent (91%)
patients have never stopped treatment without consulting their
treating physician.
Frequently, patients had occasionally postponed a dose (42.6%)
and more rarely this was a continuative behavior (3.7%). Rarely,
patients took other medicines or herbal products together with
the drug (13% as occasional episode and 3% of patients answered
“yes often”). Less than 1% of patients deliberately changed the drug
dosage without agreeing with his/her doctor, whereas only 5% of
patients forgot to reﬁll in time the drug prescription. Only 4% of
patients admitted that they had interrupted treatment due to a
sense of wellness and, on the contrary, 8% of patients discontin-
ued temporarily treatment due to an increase sense of illness after
intake. The main reasons for discontinuation were forgetfulness
(58%), side effects (14%), a sense to feel sick (5%), concomitance
with other drugs (5.6%), but none answered that discontinuation
was due to the fact that nobody had explained the importance to
be adherent to therapy. Eighty-nine percent of patients were aware
of the consequences of a scarce adherence (Fig. 1).
3.3. Relationship with treating physician and perceptions of
quality of life and adherence behaviors
On the question “What issues related to the illness and treat-
ment would you like to talk about but you can’t”, the majority of
patients (41%) reported that would like to discuss about discomfort,
anxiety and fear of the future, 18.8% of patients about psychological
problems, 12% about problems at work, 10% about relationship and
family life and 9% of patients about sexual problems.
Several methods were used to remember to be adherent to the
prescribed dose: 15% of patients used reminder on the phone or
handheld device, 18% a pill box and 17% were helped by a relative
or a friend; 26% of patients did not have the need to remind to
take medication. Twenty-eight percent of patients admitted to be
dependent from someone to be adherent to drug every day.
Only 21.5% of patients evaluated the state of QoL as perfect, 52%
as good, whereas 24% classiﬁed own  QoL as fair. A question investi-
gated about family perceptions of illness: 44% of patients answered
that own family was  relaxed and conﬁdent, 52% that family was  a
bit worried, but conﬁdent and only 4% that own family was very
worried about CML. Summarizing personal drug compliance and
estimating how many days a month, on average, the patient did
not take the drug, the majority answered that this was  for less
than 3 days (55%) and only a minority (4%) for either more than
7 days or between 4 and 7 days. As regards the importance of com-
munication, the majority of patients (73%) believe that it would be
important to share personal experience with other patients affected
by CML  and also believe that there’s need to organize regular meet-
ings regarding CML  (Fig. 2).
3.4. Perceptions about future possible discontinuation of drug
assumption
At the question “If in the future there is a perfect and long-lasting
response to the treatment, would you accept the opportunity to
interrupt the treatment for your illness?”, 49% of patients answered
that wouldn’t interrupt it because afraid of losing all the results
achieved so far, whereas 16% of patients would like to discon-
tinue due to long-term intolerance and 20% didn’t make difference
between possible discontinuation and to continue with the daily
drug.
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Fig. 2. Most relevant questions about QoL.
4. Discussion
The results of this large patient-based survey indicate that par-
ticipants who receive routinely imatinib or other TKIs accepted CML
as a chronic disease and were generally adherent to treatment. For-
getfulness and side effects were the main reasons for which patients
altered imatinib therapy. Participants also admitted to be aware of
non-adherence consequences and also indicated good communi-
cation during routine outpatient visits.
Importantly from this survey emerged that patients often wish
to discuss with their physicians about discomfort, anxiety and fear
of the future, and also other psychological problems. This is an
important ﬁnding as often these issues are not part of routine visits
and additional psychological counseling might be necessary to fur-
ther help CML  patients to cope with the disease and the fear of
disease progression.
Eliasson et al. reported intentional and unintentional reasons
for non-adherence and showed that factors that seemed to favor
adherence were dealing with side effects and using prompts
as reminders to take medicine [6]. Our results reinforced those
observed as results of the interviews conducted by the Hammer-
smith group as well as by other groups [6,10,12]. Side effects
associated to poor adherence can be managed by prompt atten-
tion and supportive care. Our study could be limited by some
bias: a self-reported questionnaire may  have inﬂuenced the results
of the survey reported here (the so-called “Hawthorne effect”)
[13]. Most studies rely upon self-reporting by patients suffer from
the bias to overestimate the rates of adherence (unwillingness to
admit a scarce adherence), and were considered by some authors
too subjective [14,15,7]. Another possible bias to keep in mind
is the rate of participation to the scheduled events: we  esti-
mated that the rate of adherence to this survey was  higher than
85%, therefore this bias could not invalidate the messages of this
study.
Another area we aimed to explore in this survey was patients’
attitude toward the possibility of stopping drug assumption.
Indeed, with the introduction of second generation TKIs and
the achievement of deeper molecular responses, it is possible to
hypothesize a future discontinuation. Several studies showed that
from 40 to 50% of patients who discontinued imatinib, remained
in molecular response without relapse if discontinuation occurred
in deep long-lasting molecular response [16–20]. Very recent CML
protocols are also further testing this possibility [21]. The results
of this study showed that patients are aware of the possibility to
discontinue TKI treatment but the majority of them (49%) would be
reluctant to interrupt therapy because afraid of losing response to
therapy. We can speculate on these results that healthcare physi-
cians should improve patient’s knowledge on making appropriate
judgment as to long-term effects from treatment, dealing with
missing doses and adverse effects reinforcing the importance of
adherence. Moreover, increased knowledge about treatment free
remission is necessary in order to illustrate the importance of deep
molecular response and possible discontinuation.
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Appendix A.
A.1. Items included in the ad-hoc Survey
(1) Have you ever forgotten to take your drug?
(2) Have you ever stopped treatment for a brief period without
consulting your doctor?
(3) Have you ever postponed a dose of medication after the sched-
uled time?
(4) Have you ever taken other medicines, nutraceuticals, vitamins
or herbal products, together with the drug without your doc-
tor’s knowledge or without consulting him/her ﬁrst?
(5) When and how often are you able to discuss your illness with
your doctors?
(6) Have you ever deliberately changed the drug dosage without
agreeing with your doctor?
(7) Do you have the possibility to speak openly with your doctors
about your treatment?
(8) Have you ever forgotten to reﬁll your drug prescription in
time?
(9) Have you ever depended on someone to remind you to take
your drug?
(10) Would it be important for you to share your experience with
other people affected by CML?
(11) Have you ever neglected your doctor’s advice regarding your
treatment?
(12) Would you like regular meetings regarding CML  to be orga-
nized between doctors and patients?
(13) Have you ever interrupted your treatment because you were
feeling better?
(14) Do you use any particular tool to remind you to take your drug?
(15) Have you ever decided to suspend your treatment because you
were not feeling well after intake?
(16) If you replied Yes to any of the above questions, what was the
reason?
(17) Are you aware of the consequences you risk if you don’t take
your drug correctly?
(18) Do you believe you’ve received sufﬁcient information from
your medical team?
(19) Who  supplies you with the drug in the center where you’re
being treated?
(20) In order to summarize your drug compliance, how many days
a month, on average, did you not take your drug correctly?
(21) How would you evaluate your quality of life in relation to the
treatment and the illness?
(22) What issues related to the illness and treatment would you
like to talk about but you can’t?
(23) How does your family feel about your illness?
(24) Do you ﬁnd that you have to limit yourself in certain daily
activities due to your illness?
(25) If in the future there is a perfect and long-lasting response to
the treatment, would you accept the opportunity to interrupt
the treatment for your illness?
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